Navigation Links
MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
Date:9/8/2010

MOUNTAIN VIEW, Calif., Sept. 8 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today reported results from a pharmacodynamics (PD) trial comparing the acute effects on pulmonary artery pressure of LEVADEX™, dihydroergotamine mesylate (DHE) administered intravenously (IV) and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

LEVADEX was well tolerated and there were no drug-related serious adverse events reported. There were no clinically significant changes in any cardiovascular parameters measured in this trial. There were no mean increases in QT interval in the LEVADEX group. All pharmacokinetic results in this trial were consistent with those reported in previous LEVADEX trials."Intravenous DHE has been used safely for over 60 years, and we wanted to evaluate whether LEVADEX, with its novel administration through the lung, would have an effect on pulmonary artery pressure. We are pleased to report that LEVADEX did not have an effect on pulmonary artery pressure compared to placebo and was, in fact, less than that seen with IV DHE," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals.

Pulmonary artery pressure in the IV DHE group was higher than both the LEVADEX and placebo groups. In addition, even after a second dose of LEVADEX was administered two hours after the first dose, pulmonary artery pressure was not higher in the LEVADEX group than in the IV DHE group.  

The PD trial was a randomized, double blind, placebo controlled, three-way, crossover trial in 24 healthy adults and was designed to compare the acute e
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
2. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
3. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
4. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
7. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
8. Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
9. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
10. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
11. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... , Inc. (NASDAQ: BIOS ) announced today that ... at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference ... , Wednesday, December 3, 2014 , , , , Time: ... Location: , , , Boca Raton Resort and Club, Florida , ... BioScrip, Inc. is a leading national provider of infusion and ...
(Date:11/26/2014)... , Nov. 26, 2014 Zynerba Pharmaceuticals ... development of innovative transdermal synthetic cannabinoid treatments, today announced ... 26th Annual Healthcare Conference 2014. The conference will be ... Palace in New York . Zynerba,s ... at 4:50 pm on Tuesday, December 2. ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... UCB and Harvard University officially launched their innovative Research ... Boston last night in the presence of his Royal ... http://photos.prnewswire.com/prnh/20110630/NY28450 ) The Alliance creates a ... Harvard scientists continuing their research that holds potential for ...
... announces that a new market research report is ... Devices & Diagnostics Equipments in India ... the Indian Medical Devices & equipments market is ... annually. India is growing as a ...
Cached Medicine Technology:UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3Medical Devices & Diagnostics Equipments in India 2Medical Devices & Diagnostics Equipments in India 3Medical Devices & Diagnostics Equipments in India 4Medical Devices & Diagnostics Equipments in India 5
(Date:11/28/2014)... November 28, 2014 Nipomo Family ... Christina Do, recently opened its doors at 195 N. ... Along with preventative care like teeth cleanings, oral exams, ... dentistry, Invisalign, teeth whitening (and Kor whitening), laser whitening, ... addition, Nipomo Family Dentistry’s five-person team also takes a ...
(Date:11/27/2014)... One of the major segments of ... implant dentistry comprises dental implants and abutments as ... dental care is bifurcated into two segments: dental ... is composed of large equipment. , View full ... , The worldwide dental market is growing ...
(Date:11/27/2014)... The report “Blepharitis – Pipeline ... therapeutic development for Blepharitis, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Blepharitis and special features on late-stage and discontinued ...
(Date:11/27/2014)... Petersburg, Fl (PRWEB) November 28, 2014 Let ... , Beautiful Christmas boxes with bows on top, filled with ... All prices are deeply discounted today while quantities last - ... . , All products are also available on Amazon at ... found on each Sublime shop product page for ease. , ...
(Date:11/27/2014)... 27, 2014 In a world ... to sleep has lessened, and due to the ... quality of sleep has eroded. According to Web ... the job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This remarkably ... by an incalculable amount, leading not only to ...
Breaking Medicine News(10 mins):Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 3Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3Health News:Blepharitis Pipeline Market Review on Drugs and Companies H2 2014 2Health News:Blepharitis Pipeline Market Review on Drugs and Companies H2 2014 3Health News:Blepharitis Pipeline Market Review on Drugs and Companies H2 2014 4Health News:Big Christmas Sales Begin Today at Sublime Beauty® for all Christmas Gift Selections and Skincare Sets 2Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2
... , SATURDAY, May 21 (HealthDay News) -- As summer ... heat-related illnesses, experts say. "We are not invincible ... Brendon McDermott, an athletic trainer with the University of ... Institute (KSI) Medical and Science Advisory Board, in a ...
... (May 20, 2011)The American Federation for Aging Research (AFAR) today ... fellows and junior faculty at 27 Centers of Excellence in ... funded with support from the John A. Hartford Foundation, has ... cadre of academic leaders in geriatrics. As our nation ages, ...
... discs in the low back wear out, become compressed and ... discs can be a viable alternative to standard fusion surgery, ... recently published in the Journal of Bone and Joint ... fusion but this is believed the first to evaluate the ...
... are treated for cancer during childhood have a significantly higher ... severe later in life, according to a study led ... the need for childhood cancer survivors and their physicians to ... health care needs are met. "We have, in a ...
... , FRIDAY, May 20 (HealthDay News) -- The number of ... in recent years, a new government study shows. Researchers ... data from birth certificates for more than 4 million live ... previous years. The investigators found that 28,357 babies were ...
... of UT Dallas is known throughout the world for his ... at The University of Texas at Dallas, he,s known to ... received the President,s Teaching Excellence Award for Tenure-Track Faculty during ... from among more than 100 eligible faculty members who were ...
Cached Medicine News:Health News:Keeping Cool in the Heat 2Health News:AFAR announces the 2011 Hartford Scholars in Geriatric Medicine 2Health News:2-year results: Artificial disc a viable alternative to fusion for 2-level disc disease 2Health News:Childhood cancer survivors at higher risk for future GI complications 2Health News:Home Births Jump 20 Percent in 4 Years: U.S. Report 2Health News:Home Births Jump 20 Percent in 4 Years: U.S. Report 3Health News:UT Dallas' Moller receives teaching award 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: